Linked Life Data

15131032

Source:http://linkedlifedata.com/resource/pubmed/id/15131032

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2004-5-7
pubmed:abstractText
To establish the maximum tolerated dose of lonafarnib, a novel farnesyltransferase inhibitor, in combination with paclitaxel in patients with solid tumors and to characterize the safety, tolerability, dose-limiting toxicity, and pharmacokinetics of this combination regimen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2968-76
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15131032-Adult, pubmed-meshheading:15131032-Aged, pubmed-meshheading:15131032-Alkyl and Aryl Transferases, pubmed-meshheading:15131032-Anemia, pubmed-meshheading:15131032-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15131032-Area Under Curve, pubmed-meshheading:15131032-Dose-Response Relationship, Drug, pubmed-meshheading:15131032-Farnesyltranstransferase, pubmed-meshheading:15131032-Fatigue, pubmed-meshheading:15131032-Female, pubmed-meshheading:15131032-Heart Arrest, pubmed-meshheading:15131032-Humans, pubmed-meshheading:15131032-Leukopenia, pubmed-meshheading:15131032-Male, pubmed-meshheading:15131032-Middle Aged, pubmed-meshheading:15131032-Neoplasms, pubmed-meshheading:15131032-Neutropenia, pubmed-meshheading:15131032-Paclitaxel, pubmed-meshheading:15131032-Piperidines, pubmed-meshheading:15131032-Pyridines, pubmed-meshheading:15131032-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
pubmed:affiliation
Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA. fkhuri@emory.edu
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I